Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone

Published:2022-01-05 Issue:1 Volume:5 Page:e2142093
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Marar Mallika¹²,Long Qi³,Mamtani Ronac⁴,Narayan Vivek⁴,Vapiwala Neha²,Parikh Ravi B.⁴⁵⁶

Affiliation:

1. Department of Radiation Oncology, Stanford University, Stanford, California

2. Perelman School of Medicine, Department of Radiation Oncology, University of Pennsylvania, Philadelphia

3. Perelman School of Medicine, Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia

4. Perelman School of Medicine, Department of Medicine, University of Pennsylvania, Philadelphia

5. Perelman School of Medicine, Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia

6. Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2787631/marar_2022_oi_211173_1640186076.50125.pdf

Reference22 articles.

1. Disparities in castration-resistant prostate cancer trials.;Spratt;J Clin Oncol,2015

2. All men are created equal: addressing disparities in prostate cancer care.;Borno;Am Soc Clin Oncol Educ Book,2019

3. Overall survival by race in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or enzalutamide.;McNamara;J Clin Oncol,2019

4. Abi Race: a prospective, multicenter study of black (B) and white (W) patients (pts) with metastatic castrate resistant prostate cancer (mCRPC) treated with abiraterone acetate and prednisone (AAP).;George;J Clin Oncol,2018

5. A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.;George;Cancer,2021

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of different visceral metastatic sites on survival in metastatic prostate cancer patients;PLOS ONE;2024-09-06

2. Androgen Deprivation Therapy and Outcomes After Radiation Therapy in Black Patients With Prostate Cancer;JAMA Network Open;2024-06-10

3. Real-world clinical outcomes among patients with metastatic castration-sensitive prostate cancer initiating apalutamide;FUTURE ONCOL;2024

4. Emerging racial disparities among Medicare beneficiaries and Veterans with metastatic castration-sensitive prostate cancer;Prostate Cancer and Prostatic Diseases;2024-04-02

5. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3